Effect of estrogen and corticosterone on the lymphoid system in neonatal mice

Altered Development of Immunocompetence Following Prenatal or Combined Prenatal-Postnatal Insult: A Timely Review

There is an unequal distribution of interest between assessment of immunocompetence at the adult level following the administration of various agents/protocols and evaluation of immunocompetence postnatally subsequent to prenatal insult. This paper reviews the effects of dietary manipulation, selected pharmaceuticals, and certain environmental agents on the functional status of the postnatal immune system after in utero exposure to these agents and protocols. These data are discussed in light of what has also been observed for adult exposure to the same or similar experimental design. A discussion of congenital disorders of immunocompetence is also provided. Alteration in the development of postnatal immunocompetence following prenatal insult may manifest itself in several ways, some of which may reflect a permanent defect while others may be of a transient nature. In either instance, however, it behooves scientists in all arenas to (1) determine the precise nature and magnitude of such developmentally related immunologic deficits and (2) focus on the selection and standardization of the most relevant procedures to be employed in the assessment of immunocompetence.

Altered immune response in adult women exposed to diethylstilbestrol in utero

OBJECTIVE

Between 1940 and 1970, 1.5 million female fetuses were exposed to diethylstilbestrol in utero. Numerous deleterious effects on reproductive anatomic and physiologic characteristics have been documented in these women. However, the effects of this exposure on nonreproductive systems, which may have lifelong consequences as this cohort of women progresses beyond the childbearing years, have received little attention. On the basis of an earlier preliminary observation of altered immune reponse, we hypothesized that diethylstilbestrol-exposed women may show abnormalities in T-cell-mediated immune response.

STUDY DESIGN

Thirteen women exposed to diethylstilbestrol in utero were compared with 13 age- and menstrual cycle phase-matched control subjects with respect to the in vitro T-cell response to the mitogens phytohemagglutinin, concanavalin A, and interleukin 2.

RESULTS

As compared with controls, tritiated thymidine incorporation by T cells harvested from diethylstilbestrol-exposed women was increased 3-fold over a range of concentrations in response to concanavalin A (P <.001), increased by 50% over a range of concentrations in response to phytohemagglutinin (P <.001), and increased 2-fold in response to the endogenous mitogen interleukin 2 (P <.05).

CONCLUSIONS

In vitro evidence suggests that women exposed to diethylstilbestrol have alterations in T-cell-mediated immunity. These changes require further attention with regard to their characterization, their role in the pathogenesis of cancer and autoimmunity, and their presence in normal women exposed to diethylstilbestrol in utero.

Environmental endocrine modulators and human health: an assessment of the biological evidence

Recently, a great deal of attention and interest has been directed toward the hypothesis that exposure, particularly in utero exposure, to certain environmental chemicals might be capable of causing a spectrum of adverse effects as a result of endocrine modulation. In particular, the hypothesis has focused on the idea that certain organochlorine and other compounds acting as weak estrogens have the capability, either alone or in combination, to produce a variety of adverse effects, including breast, testicular and prostate cancer, adverse effects on male reproductive tract, endometriosis, fertility problems, alterations of sexual behavior, learning disability or delay, and adverse effects on immune and thyroid function. While hormones are potent modulators of biochemical and physiological function, the implication that exposure to environmental hormones (e.g., xenoestrogens) has this capability is uncertain. While it is reasonable to hypothesize that exposure to estrogen-like compounds, whatever their source, could adversely affect human health, biological plausibility alone is an insufficient basis for concluding that environmental endocrine modulators have adversely affected humans. Diethylstilbestrol (DES) is a potent, synthetic estrogen administered under a variety of dosing protocols to millions of women in the belief (now known to be mistaken) that it would prevent miscarriage. As a result of this use, substantial in utero exposure to large numbers of male and female offspring occurred. Numerous studies have been conducted on the health consequences of in utero DES exposure among the adult offspring of these women. There are also extensive animal data on the effects of DES and there is a high degree of concordance between effects observed in animals and humans. The extensive human data in DES-exposed cohorts provide a useful basis for assessing the biological plausibility that potential adverse effects might occur following in utero exposure to compounds identified as environmental estrogens. The effects observed in both animals and humans following in utero exposure to sufficient doses of DES are consistent with basic principles of dose response as well as the possibility of maternal dose levels below which potential non-cancer effects may not occur. Significant differences in estrogenic potency between DES and chemicals identified to date as environmental estrogens, as well as an even larger number of naturally occurring dietary phytoestrogens, must be taken into account when inferring potential effects from in utero exposure to any of these substances. The antiestrogenic properties of many of these same exogenous compounds might also diminish net estrogenic effects. Based on the extensive data on DES-exposed cohorts, it appears unlikely that in utero exposure to usual levels of environmental estrogenic substances, from whatever source, would be sufficient to produce many of the effects (i.e., endometriosis, adverse effects on the male reproductive tract, male and female fertility problems, alterations of sexual behavior, learning problems, immune system effects or thyroid effects) hypothesized as potentially resulting from exposure to chemicals identified to date as environmental estrogens.

Effects of prenatal exposure to delta-9-tetrahydrocannabinol on reproductive, endocrine and immune parameters of male and female rat offspring

The effects of prenatal THC administration, given during the third week of gestation in rats, on the reproductive, endocrine and immune systems of the adult offspring were examined. THC treatment blocked the surge of testosterone which occurs in the male rat fetus on gestation day 18. Moreover, when copulatory parameters were measured in adult male offspring, males that had been exposed to THCin utero exhibited an increased latency to mount (THC: 245±49vs vehicle: 99±12 sec) and none of the males ejaculated. Female rats exposed to THCin utero, exhibited an increased incidence of irregular estrous cycles and the number of females exhibiting lordosis behavior was reduced when compared to vehicle controls. Hormone analyses revealed that prolactin levels were significantly lower in the THC-vs vehicle-exposed male (THC: 5.2±0.4vs vehicle: 8.4±0.6 ng/ml) and female offspring (THC: 5.7±0.3vs vehicle: 12.2±1.8 ng/ml). However, there were no significant differences in basal plasma LH levels or in testicular weights of the male offspring. Thymus weight and total number of thymocytes were significantly higher in THC-exposed male and female rats when compared to vehicle controls. Together, these results indicate that maternal THC exposure has long-lasting effects on reproductive, endocrine and immune parameters of both male and female rat offspring.

2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced thymic atrophy and lymphocyte stem cell alterations by mechanisms independent of the estrogen receptor

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) has both agonist and antagonist effects on estrogen-mediated activities and estrogen receptor (ER) levels in epithelial tissues following exposure. We previously demonstrated that TCDD alters bone marrow lymphocyte stem cells, including prothymocytes, as measured by functional assays and alterations in the lymphocyte stem cell-specific markers terminal deoxynucleotidyl transferase (TdT) and recombinase activating gene-1 (RAG-1). We have also shown that 17 beta-estradiol valerate (E2V) affects lymphocyte stem cells by reducing TdT and RAG-1 mRNA. It has been suggested that the effect of TCDD on these lymphocyte stem cells may be mediated directly or indirectly through estrogenic action and/or the ER. Studies were designed to evaluate whether endogenous estrogens or the ER mediate TCDD-elicited bone marrow alterations and thymic atrophy. Ovariectomy did not alter the sensitivity of mice to TCDD-induced thymic atrophy or to a reduction in TdT biosynthesis in bone marrow cells compared with either intact or sham-operated mice. The pure estrogen antagonist ICI 164,384 blocked E2V-induced uterine hypertrophy, thymic atrophy and reductions in lymphocyte stem cell markers. However, the antiestrogen failed to protect against TCDD-elicited thymic atrophy or bone marrow alterations in intact animals. The results are consistent with the hypothesis that the effects of TCDD on the thymus and/or bone marrow are mediated by mechanisms independent of estrogens or the ER.

Short-term and long-term effects of estrogen on lymphoid tissues and lymphoid cells with some remarks on the significance for carcinogenesis

Estrogens have long been thought to play a role in regulating the immune system. The difference in some types of immune responses between males and females is well-known, as is the pronounced thymic involution induced by exogenous estrogens. Estrogens stimulate some aspects of macrophage activity and, depending on dose and mitogen, inhibit or stimulate lymphocyte proliferative response in vitro. Another example is the estrogen effect on the delayed type hypersensitivity response. A broad review is given of such estrogen effects on lymphoid tissue and immune response. Most of the studies published so far are phenomenological. However, the recent description of estrogen receptors in the thymus and in some lymphocyte subpopulations, as well as a deeper understanding of regulating factors in the immune system, open the possibility of a more detailed understanding of the estrogen mechanism of interference. Estrogen effects in adults are reversible. After treating neonatal mice with the synthetic estrogen diethylstilbestrol (DES), disturbances are induced in lymphocyte populations and lymphocyte functions which are permanent and irreversible. Lymphocytes from adult, neonatally DES-treated female mice have a reduced mitogen response to ConA and LPS (T and B cell mitogen) and the delayed type hypersensitivity response is depressed. A detailed analysis demonstrated a decreased T helper cell population. The activity of Natural Killer cells is permanently reduced and this functional impairment is related to a decreased number of these cells, in turn determined at the bone marrow level. The same animals have an increased sensitivity to chemical carcinogens (methylcholanthrene) and they spontaneously develop epithelial changes in the uterine cervix which morphologically are similar to adenocarcinoma. The association between estrogen-associated malignancy and estrogen effects in lymphocyte functions deserves further study.

Mechanisms of estrogen-induced myelotoxicity: evidence of thymic regulation

Mice exposed to pharmacological levels of steroidal and nonsteroidal estrogens including alpha-dienestrol, 17 beta-estradiol, and diethylstilbestrol demonstrate bone marrow hypocellularity, and decreased numbers of pluipotent hemopoietic stem cells. Hormones with little estrogenic activity including testosterone and progesterone failed to induce myelotoxicity as did nonestrogenic metabolites of DES. Myelotoxicity associated with estrogen exposure is regulated by a complex bimodal mechanism. One of these mechanisms is mediated through the thymus since surgical thymectomy abolished the ability of estrogens to suppress CFU proliferation. Furthermore, supernatants of thymic epithelial cells cultured in the presence of estradiol were capable of inhibiting CFU-GM colony formation. Specific myelotoxic events can also be disassociated chemically by testing weakly estrogenic compounds such as zearalanol which shows different sensitivity on cytoxic and antiproliferative events. Myelotoxicity is not mediated indirectly through the ovary or adrenal gland. That the initial events in estrogen-induced myelotoxicity may be mediated through a receptor mechanism was suggested by the ability of antiestrogens to induce antagonism when administered prior to estradiol and the presence of estrogen binding components in lymphoreticular tissues including the thymus and bone marrow. These studies suggest that reduced CFU kinetics observed following estrogen exposure is, in part, due to alterations in regulatory factors produced by thymic epithelial cells in response to a specific estrogen stimulus. Estrogens may also influence bone marrow functions through non-thymic mechanisms at higher dose levels.

Carbon dioxide laser treatment of vaginal adenosis in DES-exposed offspring: a prospective study

Seventy-nine patients with history and physical findings characteristic of antenatal DES exposure were randomly divided into two groups. Fourty-four DES-exposed offspring had their vaginal adenosis treated with the carbon dioxide laser (group I), and the remaining 35 DES-exposed offspring (group II) did not receive any specific treatment for this condition. Additionally, the 79 DES-exposed offspring were compared to an age-matched control population (group III). Treatment of vaginal adenosis with the carbon dioxide laser did not significantly reduce the incidence of development of new dysplasia in the DES-exposed offspring. This study also showed no statistical difference (p less than or equal to 0.05) in the incidence of dysplasia in DES-exposed offspring as compared to a control population.

Effect of diethylstilbestrol and estramustine phosphate (Estracyt) on delayed hypersensitivity response to oxazolone in male mice

The effects of diethylstilbestrol (DES) and estramustine phosphate (EMP) on delayed hypersensitivity response (DTH) to oxazolone in male mice were investigated using a radioisotopic ear method. DES significantly inhibited the ability to express a DTH response and was most effective when given during the effector phase of the reaction. EMP had no effects when the animals were exposed to the drug during the effector phase, while it resulted in a strong and dose-dependent depression of the DTH response when applied in the sensitization phase. Possible involvement of suppressor cells was investigated by pretreatment of animals with cyclophosphamide or by adoptive transfer of tentative suppressor cells from spleen, lymph nodes, or peritoneal cavity. However, no evidence of cellular or humoral suppressor factors induced by drug treatment was found.

Ovarian influence on mitogen responsiveness of lymphocytes from mice neonatally exposed to diethylstilbestrol

Treatment of neonatal female mice with diethylstilbestrol (DES) resulted in a reduced response of spleen lymphocytes to concanavalin A (Con A) and lipopolysaccharide (LPS). Ovariectomy or ovariectomy plus estradiol treatment had no influence on the response to Con A in either control or DES-treated females. Ovariectomy reduced the response to LPS in control animals and eliminated the difference between control and DES-treated females. Estradiol treatment enhanced the response of ovariectomized control females to LPS and restored the difference between control and DES-treated animals. Comparison of the mitogen responsiveness during various stages of the estrous cycle showed a tendency for the response to be augmented at proestrus and metestrus, although the differences were not significant.

Physiological mechanisms of diethylstilbestrol organotropic carcinogenesis

Treatment of pregnant women with diethylstilbestrol (DES) during pregnancy has been demonstrated to be associated with an increased risk in the female offspring for development of an otherwise very rare type of malignancy: clear-cell adenocarcinoma of the vagina and cervix. The present knowledge about this association is reviewed. In experimental animals, many different types of malignancy can be induced by DES administered in large doses and during long periods. For the human situation there are as yet no indications that exposure to DES during fetal life has resulted in any generally increased incidence of malignant tumors. By injecting neonatal mice with DES for the first five days after birth, histologically malignant changes develope in the uterine cervix of the animals when more than one year old. A comparison is made between this animal model and development of tumors in the human female offspring of DES treated mothers. In the female mice, neonatal DES treatment results in a disturbed epithelial differentiation process in the upper part of the vagina and the uterine cervix, a disturbed development of the hypothalamic-pituitary gland control system as well as a disturbance in the normal development of the lymphoid system. The abnormal epithelial differentiation process results in development of adenosis and within these areas the malignant changes later appear. We do no know whether adenosis is a pre-cancerous condition or not, in the meaning that it contains dormant malignant cells. Other factors could act upon adenosis to result in cancer. The reasons for DES being called a "carcinogen" are reviewed. The possibility for factors in the environment acting as potential transplacental carcinogens in the human fetus should not be excluded.